Market Closed -
Nasdaq
04:00:00 2024-05-17 pm EDT
|
5-day change
|
1st Jan Change
|
2.74
USD
|
-1.44%
|
|
+11.38%
|
+41.24%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,861
|
865.2
|
488.6
|
698.5
|
-
|
-
|
Enterprise Value (EV)
1 |
1,634
|
225
|
-57.6
|
577.4
|
227.9
|
459
|
P/E ratio
|
-4.21
x
|
-4.69
x
|
-2.09
x
|
-3.16
x
|
-3.02
x
|
-3.07
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
175
x
|
10.2
x
|
3,759
x
|
349,267
x
|
140
x
|
-
|
EV / Revenue
|
153
x
|
2.66
x
|
-443
x
|
288,706
x
|
45.6
x
|
-
|
EV / EBITDA
|
-8.12
x
|
-1.33
x
|
0.25
x
|
-2.64
x
|
-0.82
x
|
-1.13
x
|
EV / FCF
|
-8.52
x
|
-1.16
x
|
0.35
x
|
-3.68
x
|
-1.33
x
|
-2.2
x
|
FCF Yield
|
-11.7%
|
-86.1%
|
289%
|
-27.2%
|
-75%
|
-45.5%
|
Price to Book
|
2.02
x
|
1.04
x
|
0.75
x
|
1.07
x
|
1.06
x
|
-
|
Nbr of stocks (in thousands)
|
240,471
|
249,326
|
251,869
|
254,939
|
-
|
-
|
Reference price
2 |
7.740
|
3.470
|
1.940
|
2.740
|
2.740
|
2.740
|
Announcement Date
|
3/29/22
|
2/28/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
10.65
|
84.68
|
0.13
|
0.002
|
5
|
-
|
EBITDA
1 |
-
|
-201.2
|
-169
|
-226.8
|
-218.4
|
-278.2
|
-406.6
|
EBIT
1 |
-
|
-214.8
|
-187.1
|
-247
|
-229
|
-270.9
|
-350.4
|
Operating Margin
|
-
|
-2,016.68%
|
-220.89%
|
-190,006.15%
|
-11,452,355.5%
|
-5,418.96%
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-183.1
|
-234.6
|
-222.1
|
-253.2
|
-334.5
|
Net income
1 |
-204.5
|
-250.2
|
-183.1
|
-234.6
|
-222.1
|
-253.2
|
-334.5
|
Net margin
|
-
|
-2,349.47%
|
-216.24%
|
-180,486.15%
|
-11,106,211%
|
-5,064.57%
|
-
|
EPS
2 |
-
|
-1.840
|
-0.7400
|
-0.9300
|
-0.8671
|
-0.9061
|
-0.8921
|
Free Cash Flow
1 |
-
|
-191.8
|
-193.8
|
-166.4
|
-157
|
-171
|
-209
|
FCF margin
|
-
|
-1,800.5%
|
-228.89%
|
-127,984.62%
|
-7,850,000%
|
-3,420%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/12/21
|
3/29/22
|
2/28/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
2.822
|
0.553
|
35.74
|
0.003
|
48.39
|
0.065
|
0.027
|
0.025
|
0.013
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-60.84
|
-53.94
|
-54.45
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-47.54
|
-68.58
|
-37.26
|
-66.44
|
-14.78
|
-62.56
|
-65.9
|
-59.04
|
-59.51
|
-55.58
|
-55.95
|
-57.68
|
-60.1
|
-64.5
|
-56.5
|
Operating Margin
|
-1,684.55%
|
-12,400.72%
|
-104.25%
|
-2,214,566.67%
|
-30.55%
|
-96,240%
|
-244,092.59%
|
-236,156%
|
-457,753.85%
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-68.14
|
-36.32
|
-70.25
|
-8.397
|
-66.96
|
-63.89
|
-50.85
|
-52.93
|
-60.67
|
-49.07
|
-50.46
|
-51.8
|
-50.24
|
-52.6
|
Net income
1 |
-83.71
|
-68.14
|
-36.32
|
-70.25
|
-8.397
|
-66.96
|
-63.89
|
-50.85
|
-52.93
|
-60.67
|
-49.07
|
-50.46
|
-51.8
|
-50.24
|
-52.6
|
Net margin
|
-2,966.19%
|
-12,322.6%
|
-101.63%
|
-2,341,800%
|
-17.35%
|
-103,013.85%
|
-236,629.63%
|
-203,412%
|
-407,153.85%
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.1800
|
-0.2800
|
-0.1500
|
-0.2800
|
-0.0300
|
-0.2700
|
-0.2600
|
-0.2000
|
-0.2000
|
-0.2400
|
-0.1965
|
-0.2059
|
-0.2142
|
-0.2350
|
-0.2100
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/29/22
|
5/10/22
|
8/4/22
|
11/8/22
|
2/28/23
|
5/4/23
|
8/8/23
|
11/7/23
|
2/28/24
|
5/6/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
227
|
640
|
546
|
121
|
471
|
240
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-192
|
-194
|
-166
|
-157
|
-171
|
-209
|
ROE (net income / shareholders' equity)
|
-
|
-78.5%
|
-20.8%
|
-31.5%
|
-38.5%
|
-41.3%
|
-66.9%
|
ROA (Net income/ Total Assets)
|
-
|
-24.6%
|
-17.7%
|
-27.8%
|
-33.1%
|
-42.4%
|
-54%
|
Assets
1 |
-
|
1,018
|
1,032
|
843.8
|
671.8
|
597.4
|
619.2
|
Book Value Per Share
2 |
-
|
3.830
|
3.340
|
2.580
|
2.560
|
2.580
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
65.5
|
24.3
|
2.69
|
3
|
3
|
3
|
Capex / Sales
|
-
|
615.06%
|
28.67%
|
2,066.15%
|
150,000%
|
60%
|
-
|
Announcement Date
|
5/12/21
|
3/29/22
|
2/28/23
|
2/28/24
|
-
|
-
|
-
|
Last Close Price
2.74
USD Average target price
6.333
USD Spread / Average Target +131.14% Consensus |
1st Jan change
|
Capi.
|
---|
| +41.24% | 699M | | +9.42% | 115B | | +11.84% | 106B | | -1.05% | 21.96B | | -14.15% | 21.87B | | -5.29% | 19.21B | | -4.16% | 18.08B | | -38.29% | 17.71B | | +7.99% | 14.32B | | +36.24% | 12.42B |
Bio Therapeutic Drugs
|